CJC-1295 with DAC Quotation Checklist — this article examines published research context, laboratory applications, and procurement notes for CJC-1295 with DAC (5mg) in Growth Research programs at Sulan Peptide Official.
CJC-1295 with DAC is a modified GHRH analog peptide used in laboratory research on growth-hormone-axis signaling, peptide half-life extension, and receptor-pathway studies involving DAC-mediated albumin binding.
Sulan Peptide lists CJC-1295 with DAC in the Growth Research category for qualified buyers comparing GHRH analog products, vial format, Cat No. references, and quotation details.
This page is designed to support research-use review only, including molecular specifications, purity target, storage guidance, and procurement information for the 5mg format.
Laboratories preparing CJC-1295 with DAC protocols commonly pair the material with Sterile Bacteriostatic Water (BAC), Precision laboratory pipettes, Low-bind microtubes, Vial storage organizers (-20°C). These are workflow accessories—not bundled in the vial.
Research teams working with CJC-1295 with DAC often include Growth-axis research labs, GHRH pathway research teams, Peptide half-life research groups, Preclinical peptide pharmacology groups, Qualified peptide procurement teams. These groups typically require documented peptide identity, batch COA review, and RUO compliance before releasing material into cell or animal protocols.
CJC-1295 with DAC incorporates a Drug Affinity Complex (maleimidopropionyl linker) extending half-life in GHRH receptor binding studies.
Research compares DAC-modified GHRH(1-29) analogs against native GHRH pulses in pituitary somatotroph cell lines measuring GH secretagogue responses.
GH release ELISA from primary pituitary cultures and GHRH receptor internalization microscopy are common assay endpoints.
Endocrine society abstracts and journal articles discuss prolonged GHRH analog exposure effects on pulsatile GH secretory pattern models in swine and rodent systems.
Quotation preparation: Example subject — Quote request: CJC-1295 with DAC (5mg) | Qty [X] | Destination [Country]. Attach the product URL from sulanpeptide.shop and list required COA or Janoshik documentation.
Available CJC-1295 with DAC research formats on sulanpeptide.shop include 5mg*10vials. Cat No. references (CD5) should appear on requisitions so quoted material matches the specification selected during protocol design.
Multi-line quotes including CJC-1295 with DAC are easier to confirm when Cat No. and specification appear in a table format with RUO acknowledgment and shipping preferences in the same message.
Purity target ≥ 99.0% on the catalog is a specification goal—your QA team should confirm the specific lot COA meets internal thresholds before release.
When CJC-1295 with DAC appears in combination with other peptides, cite each sequence’s Cat No. in publications to satisfy reproducibility standards in Growth Research journals.
Statistical plans should pre-register primary endpoints before unblinding CJC-1295 with DAC treatment arms in preclinical models.
Shipping seasonality can affect lyophilized cake integrity for CJC-1295 with DAC; inspect vials after extreme transit delays even if COA predates shipment.
Training records for staff handling CJC-1295 with DAC should cover reconstitution math, RUO policy, and spill cleanup for research laboratories.
Dose–response studies with CJC-1295 with DAC typically span log-scale concentrations; your protocol should state whether dosing is by mass (5mg) or molarity derived from molecular weight on the product page.
Published Growth Research papers often include positive and negative assay controls alongside CJC-1295 with DAC; budget control compounds before ordering experimental material.
When designing multi-arm studies, randomize vial lot assignment and blind analysts to supplier identity until primary readouts are locked—this reduces bias in vendor comparison experiments involving CJC-1295 with DAC.
Catalog specification data for CJC-1295 with DAC lists CAS 446262-90-4, Molecular formula C165H269N47O46. molecular weight 3647.25 g/mol, and purity target ≥ 99.0%. Match these identifiers to incoming COA documents and internal sample labels before assay use.
Supplier storage guidance for CJC-1295 with DAC: Store at -20°C, in a cool and dry place. Log receipt date, lot number, and freezer location when material enters your inventory. Plan aliquots before reconstitution to limit freeze-thaw cycles during multi-week assay series.
Cell viability panels should precede mechanism assays when introducing CJC-1295 with DAC to new cell lines—unexpected toxicity may reflect solvent choice rather than peptide sequence.
For long-horizon Growth Research projects, document freezer location and thaw count on every aliquot label tied to CJC-1295 with DAC lot numbers.
Appearance notes (White Lyophilized Powder) help detect moisture exposure or handling damage during receiving inspection of CJC-1295 with DAC.
Internal IRB or IACUC protocols should cite RUO scope explicitly when CJC-1295 with DAC appears in animal or human-derived tissue research models.
Compare published assay incubation times for CJC-1295 with DAC; overnight versus short pulses can invert apparent potency rankings in receptor assays.
Literature searches for CJC-1295 with DAC should use both trade names and CAS 446262-90-4 to capture mechanistic papers missed by supplier marketing keywords alone.
Pilot experiments with CJC-1295 with DAC often start at mid-range catalog specifications (5mg) before scaling quantity for full study cohorts.
CJC-1295 with DAC from Sulan Peptide Official is supplied for research use only (RUO)—not for human or veterinary use, diagnosis, or treatment. Direct specification or quotation questions via the Contact page or WhatsApp on sulanpeptide.shop.